Hip Joint Distension in Osteoarthrosis. A Triple-Blind Controlled Study Comparing the Effect of Intra-Articular Indoprofen With Placebo

Scand J Rheumatol. 1984;13(3):238-42. doi: 10.3109/03009748409100392.

Abstract

In a triple-blind controlled study, significant pain alleviation (p less than 0.01) was registered in patients with osteoarthrosis (OA) of the hip in the first 24 h after hip joint distension. There was no significant difference between treatment with indoprofen (a new non-steroidal anti-inflammatory drug for intra-articular use) and placebo. Pain relief lasted for at least 12 weeks in approximately half of the patients, in whom a significant increase in joint mobility was registered. Intra-articular indoprofen was not superior to placebo as regards pain relief or increased joint mobility. These findings indicate that the effect of a single hip joint distension in OA is due to a mechanical distension of the joint capsule, perhaps involving disruption of local agglutinations, and not due to suppression of inflammation.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Clinical Trials as Topic
  • Female
  • Hip Joint / pathology*
  • Humans
  • Indoprofen / administration & dosage
  • Indoprofen / therapeutic use*
  • Injections, Intra-Articular
  • Male
  • Middle Aged
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / physiopathology
  • Osteoarthritis / therapy
  • Pain / drug therapy
  • Pain / etiology
  • Phenylpropionates / therapeutic use*
  • Placebos

Substances

  • Phenylpropionates
  • Placebos
  • Indoprofen